Dilon Diagnostics will introduce the latest advancement in molecular breast imaging (MBI) this week at the Society of Nuclear Medicine (SNM) Meeting in San Antonio, Texas, with the premiere of its FDA-cleared Dilon 6800® Acella Gamma Camera system. To complement the already widely successful Dilon 6800® standard field-of-view imaging system, the new camera will feature a much larger MBI detector which will make Dilon the first company in the industry to offer customers a choice in detector sizes.

MBI, also referred to as Breast-Specific Gamma Imaging (BSGI), is a functional imaging technique increasingly being used in the diagnostic workup of patients with indeterminate mammograms, particularly for those with dense breasts. With more than 250,000 patients imaged worldwide and an expanding number of molecular imaging products, Dilon is leading the forefront in molecular imaging and supporting clinical data for early cancer diagnostics.  Dilon believes its continued success can, in part, be attributed to its focus on the individual needs of each healthcare facility and personalized healthcare by providing customers with ongoing advancements such as larger field-of-view detectors and products like GammaLoc® (the only FDA-cleared biopsy guidance platform for MBI).  

According to Robert G. Moussa, Chairman and CEO at Dilon Diagnostics, "With the increasing need to better serve a diversifying population of women, we feel it is crucial to provide additional solutions to help facilities reduce tiling, examination times and ultimately, continue to optimize their workflow."

"With the launch of the Acella," said Moussa, "I am proud to say that we are now the only molecular breast imaging company in the industry who has the unique capability of being able to offer customers a choice of imaging solutions."